FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
houre por roeponeo:								

					-						прапу Аст									
Name and Address of Reporting Person*  Formula M. Address of Reporting Person*						2. Issuer Name <b>and</b> Ticker or Trading Symbol  Cyclacel Pharmaceuticals, Inc. [ CYCC ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Ferguson Kenneth M.</u>				-	<u> </u>								X Directo	ector		10% Ov	vner			
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 06/14/2022							_	Officer below)	(give title		Other (s below)	specify		
C/O CYCLACEL PHARMACEUTICALS, INC.,			NC.,		1															
200 CON	NELL DR	IVE, SUITE 150	00		_									_						
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year) 06/16/2022								Line	6. Individual or Joint/Group Filing (Check Applicable Line)					
BERKEI	N	J	07922													Form filed by One Reporting Person  Form filed by More than One Reporting				
HEIGHT																Person				
(City)	(S	itate)	(Zip)																	
		Tab	le I - No	n-Deriv	ativ	e Se	curities	s Acc	quired,	Dis	posed o	f, or	Bene	eficiall	y Owned					
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution [		Date,	Code (Instr.		(4) or			Benefici	es ally Following	Form (D) o	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
												v	Price	Transac	Transaction(s) (Instr. 3 and 4)			(111511.4)		
Common Stock 06/14			/2022			A		23,733 <sup>(1)(2)</sup> A		\$0	23	23,733		D						
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date, T	l. Fransa Code (		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e los s li liy l	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisal		Expiration Date	Title	0 1	Amount or Number of Shares						
Stock Option	\$1.11	06/14/2022			A		47,467		06/14/202	23 (	06/14/2032	Comi	mon 2	17,467	\$0 <sup>(3)(4)</sup>	47,46	7	D		

## **Explanation of Responses:**

buy)

- 1. The Reporting Person received an award of 23,733 restricted stock units on June 14, 2022, which shall vest in three equal installments on June 14, 2023, June 14, 2024, and June 14, 2025.
- 2. This Form 4 is being amended to correct a typographical error in the number of restricted stock units granted to the Reporting Person on June 14, 2022. 23,733 shares of restricted stock units were granted to the Reporting Person.
- 3. The option will vest and become exercisable in equal monthly installments for thirty-six months beginning on the date of the grant, which is June 14, 2022, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date.
- 4. These options were granted to Mr. Ferguson for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.

/s/ Kenneth M. Ferguson

\*\* Signature of Reporting Person Date

06/17/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.